Revolution Medicines (NASDAQ:RVMD) Insider Sells $1,182,567.08 in Stock

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Mark Goldsmith sold 15,394 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $76.82, for a total value of $1,182,567.08. Following the completion of the sale, the insider directly owned 232,469 shares of the company’s stock, valued at approximately $17,858,268.58. This trade represents a 6.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Revolution Medicines Stock Up 3.7%

Shares of NASDAQ RVMD opened at $78.78 on Friday. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $81.49. The company has a debt-to-equity ratio of 0.16, a quick ratio of 8.05 and a current ratio of 8.05. The stock has a market cap of $15.23 billion, a P/E ratio of -15.24 and a beta of 0.96. The firm has a 50 day moving average price of $66.73 and a 200 day moving average price of $49.27.

Revolution Medicines (NASDAQ:RVMD) last posted its earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same period in the prior year, the business posted ($0.94) EPS. Analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Institutional Trading of Revolution Medicines

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. GAMMA Investing LLC boosted its holdings in Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company’s stock worth $39,000 after purchasing an additional 260 shares during the last quarter. Public Employees Retirement System of Ohio lifted its position in Revolution Medicines by 0.6% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 54,143 shares of the company’s stock worth $2,528,000 after buying an additional 336 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Revolution Medicines by 0.3% during the 2nd quarter. California State Teachers Retirement System now owns 140,077 shares of the company’s stock worth $5,153,000 after buying an additional 437 shares during the last quarter. CWM LLC grew its holdings in shares of Revolution Medicines by 171.3% in the 2nd quarter. CWM LLC now owns 917 shares of the company’s stock valued at $34,000 after acquiring an additional 579 shares in the last quarter. Finally, Arizona State Retirement System increased its position in shares of Revolution Medicines by 1.6% in the third quarter. Arizona State Retirement System now owns 41,299 shares of the company’s stock valued at $1,929,000 after acquiring an additional 646 shares during the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently commented on RVMD. Mizuho initiated coverage on Revolution Medicines in a research report on Tuesday, October 21st. They set an “outperform” rating and a $90.00 price target on the stock. Stifel Nicolaus started coverage on shares of Revolution Medicines in a report on Wednesday, October 15th. They set a “buy” rating and a $85.00 target price on the stock. Needham & Company LLC lifted their price target on shares of Revolution Medicines from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Wolfe Research initiated coverage on shares of Revolution Medicines in a research report on Tuesday, November 18th. They set an “outperform” rating and a $75.00 price objective for the company. Finally, Truist Financial began coverage on shares of Revolution Medicines in a report on Friday, September 5th. They set a “buy” rating and a $99.00 price objective on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines currently has an average rating of “Buy” and an average price target of $78.50.

Key Stores Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: First patient randomized in RASolute‑304 (daraxonrasib) resectable pancreatic cancer trial — a near‑term clinical milestone that validates program progress and can support longer‑term revenue potential if subsequent data are positive. Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial
• Neutral Sentiment: Analyst coverage remains largely positive (consensus Buy/Strong Buy with an average target near $78.50), which provides support for the stock but already factors in pipeline strengths.
• Neutral Sentiment: Institutional ownership is very high (reported ~94%); recent reported changes were small. High institutional concentration can amplify moves on news but also limits free float liquidity. RVMD Institutional Ownership and Stock Profile
• Negative Sentiment: Several insiders sold meaningful share blocks (CFO Jack Anders, COO Margaret Horn and other executives sold on Dec. 16), which can be interpreted as profit‑taking or a signal for caution; aggregated insider selling may weigh on sentiment near term. Insider Selling: Revolution Medicines (NASDAQ:RVMD) CFO Sells 3,104 Shares of Stock

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.